Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 6/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283708 | 0.90 | ALDH1A1 (0.58) | AGERNPY5RTSHRALDH1A1L3MBTL1 | |
| SCHEMBL1283582 | 0.84 | AGER (0.72) | AGERMGLL | |
| SCHEMBL1283049 | 0.83 | AGER (0.52) | AGER | |
| SCHEMBL1283673 | 0.82 | AGER (0.57) | AGERMAPTSMN1; SMN2LMNA | |
| SCHEMBL1283530 | 0.80 | AGER (0.52) | AGERMAPTSMN1; SMN2 | |
| SCHEMBL1282765 | 0.79 | AGER (0.60) | AGERMAPTSMN1; SMN2LMNA | |
| SCHEMBL1283836 | 0.77 | AGER (0.78) | AGER | |
| SCHEMBL1284194 | 0.76 | AGER (0.53) | AGERMAPTSMN1; SMN2LMNA | |
| SCHEMBL1284100 | 0.76 | AGER (0.55) | AGERL3MBTL1MAPTSMN1; SMN2LMNA | |
| SCHEMBL6895313 | 0.76 | AGER (0.51) | AGERL3MBTL1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885NPY5R 664/4885TSHR 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.